- Home
- SEED vs CUE Comparison
SEED vs CUE Comparison
Compare SEED & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | CUE |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.6M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SEED | CUE |
|---|---|---|
| Price | $1.13 | $21.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 20.0K | ★ 965.7K |
| Earning Date | 01-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.82 | $0.17 |
| 52 Week High | $2.49 | $41.42 |
Technical Indicators
Market Signals| Indicator | SEED | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 53.90 |
| Support Level | $1.05 | $0.30 |
| Resistance Level | $1.35 | $41.42 |
| Average True Range (ATR) | 0.06 | 4.04 |
| MACD | -0.00 | -1.89 |
| Stochastic Oscillator | 23.33 | 14.17 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.